Posted on Sep 16 2019 9:40 AM

"Regenerative Medicine Market 2019 Global Technology, Consumption, Segmentation, Growth, Development, Trends and forecasts to 2026"

The Global Regenerative Medicine Market is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. According to a report published by Fortune Business Insights, titled “Regenerative Medicine: Global Regenerative Medicine Market Analysis, Insights and Forecast, 2019-2026,” the market was valued at US$ 23,841.5 Mn in 2018.

Browse Complete Report [email protected] https://www.fortunebusinessinsights.com/industry-reports/regenerative-medicine-market-100970

Integra LifeSciences’ Latest Product Offering Will Favor Market Growth

The advancements in regenerative medicine have fueled their demand across the world. Increasing product launches have contributed to the rising uptake of regenerative medicine across the world. In 2017, Integra LifeSciences announced the launch of Integra Dermal Regeneration Template Single Layer ‘Thin’. The product was aimed at repairing dermal defects in a one-step procedure. The medicine will also aid in reducing hospital stays. Fortune Business Insights has identified Integra’s latest product offering as a major market growth driver. The report includes product launches, similar to Integra’s latest medicine and gauges the impact of these products on the global regenerative medicine market in the coming years.

Fortune Business Insights some of the leading companies that have made significant growth contributions to the global market. Besides this, the report identifies some of the attractive business strategies that have been adopted by renowned companies in the world. Some of the leading companies that are operating in the market are Integra LifeSciences Corporation, CELGENE CORPORATION, Medtronic, American CryoStem Corporation, Tissue Regenix, Avita Medical, Osiris Therapeutics, Inc., Wright Medical Group N.V., Smith & Nephew, and Integra LifeSciences Corporation.

Get PDF Brochure of this [email protected] https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/regenerative-medicine-market-100970

Segmentation

By Product

  • Cell Therapy
  • Gene Therapy
  • Tissue Engineering
  • Platelet Rich Plasma

By Application

  • Orthopedics
  • Wound Care
  • Oncology
  • Others

By Distribution Channel

  • Hospitals
  • Clinics

Novartis Receives EU Approval for Luxturna

The severity of chronic diseases has led to the demand for efficient medicines. The ability of regenerative medicine to treat severe life-threatening diseases in an efficient manner has created a huge demand for the products across the world. Increasing drug approvals have contributed to the rising uptake for regenerative medicines. In 2018, Novartis received usage approval from the European Union for its latest regenerative medicine ‘Luxturna’. The drug was used to treat and restore sight for people with vision impairment. Luxturna was widely useful in treatment of rare retinal diseases. Fortune Business Insights states that the approval for Luxturna will contribute to the growth of the global regenerative medicine market in the forthcoming years.

More Trending Topics From Fortune Business [email protected]

Alpha-1 Antitrypsin Deficiency (AATD) Augmentation Therapy Market to Reach US$ 1959.8 Mn by 2026, Favoured by Grifols’ Worldwide Promotion for AlfaCare, Says Fortune Business Insights

Veterinary Drugs Market to reach US$ 27,570.0 Mn by 2025, at a CAGR of 5.6% | Exclusive Report by Fortune Business Insights